RBC Life Sciences, Inc.
RBCL
$0.0001
$0.000.00%
| 09/30/2015 | 06/30/2015 | ||||
|---|---|---|---|---|---|
| Revenue | -12.70% | 15.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.70% | 15.53% | |||
| Cost of Revenue | -15.20% | 16.53% | |||
| Gross Profit | -10.77% | 14.78% | |||
| SG&A Expenses | 12.61% | -1.54% | |||
| Depreciation & Amortization | -0.84% | 39.07% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.82% | 5.89% | |||
| Operating Income | -274.89% | 60.67% | |||
| Income Before Tax | 272.60% | 59.19% | |||
| Income Tax Expenses | 389.49% | 67.77% | |||
| Earnings from Continuing Operations | 234.65% | 55.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 234.65% | 55.35% | |||
| EBIT | -274.89% | 60.67% | |||
| EBITDA | -550.58% | 76.50% | |||
| EPS Basic | 234.68% | 55.35% | |||
| Normalized Basic EPS | -251.52% | 59.18% | |||
| EPS Diluted | 234.68% | 55.60% | |||
| Normalized Diluted EPS | -251.52% | 59.18% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
